Sunny H. Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sunny H. Kim has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Arshad Jamal Ansari
Department of Pharmacology and Pharmaceutical Sciences Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles CA USA
2 shared publications Guoyun Kao
Department of Pharmacology and Pharmaceutical Sciences Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles CA USA
2 shared publicationsSrinivasarao Singireddi
Department of Pharmacology and Pharmaceutical Sciences Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles CA USA
2 shared publications- Yong Zhang
University of Southern California
2 shared publications Zeyu Zhang
Department of Pharmacology and Pharmaceutical Sciences Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles CA USA
2 shared publicationsBenjamin B. Katz
Department of Chemistry University of California Irvine CA USA
1 shared publication
Latest Publications
- Open Access
- 21 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e18329
Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases
Armed with two distinct targeting moieties, artificially created bispecific agents can uniquely modulate various processes and events implicated in human health and diseases. Despite recent approvals of multiple bispecific therapeutics, generation of homogeneous dual‐targeting constructs with desired pharmacological properties remains technically challenging. Here, we report a strategy for synthesis of bispecific agents by utilizing CD38, a member of the ADP‐ribosyl cyclase family, and its covalent inhibitor. A model ADP‐ribosyl cyclase‐enabled bispecific conjugate (ARC‐BsC) against human T‐cell CD3 and prostate‐specific membrane antigen (PSMA) is generated through site‐specific conjugation of an anti‐CD3 antibody‐CD38 fusion with the CD38 covalent inhibitor derivatized by a PSMA small‐molecule ligand. The resulting ARC‐BsC can redirect and activate cytotoxic T cells toward killing PSMA‐expressing tumor cells, eliciting highly potent and selective anti‐cancer immunity in vitro and in vivo. This proof‐of‐concept work demonstrates ARC‐BsC as a potentially general approach for the development of bispecific therapeutics with diverse applications.
- 21 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e18329
Open AccessSynthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases
Armed with two distinct targeting moieties, artificially created bispecific agents can uniquely modulate various processes and events implicated in human health and diseases. Despite recent approvals of multiple bispecific therapeutics, generation of homogeneous dual‐targeting constructs with desired pharmacological properties remains technically challenging. Here, we report a strategy for synthesis of bispecific agents by utilizing CD38, a member of the ADP‐ribosyl cyclase family, and its covalent inhibitor. A model ADP‐ribosyl cyclase‐enabled bispecific conjugate (ARC‐BsC) against human T‐cell CD3 and prostate‐specific membrane antigen (PSMA) is generated through site‐specific conjugation of an anti‐CD3 antibody‐CD38 fusion with the CD38 covalent inhibitor derivatized by a PSMA small‐molecule ligand. The resulting ARC‐BsC can redirect and activate cytotoxic T cells toward killing PSMA‐expressing tumor cells, eliciting highly potent and selective anti‐cancer immunity in vitro and in vivo. This proof‐of‐concept work demonstrates ARC‐BsC as a potentially general approach for the development of bispecific therapeutics with diverse applications.
- Open Access
- 17 June 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 189, 118274
Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases
- 17 June 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 189, 118274
Open AccessTargeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases